持续痰嗜酸性粒细胞增多症无应答者从美波珠单抗切换到贝纳利珠单抗时的严重哮喘结局

Biologics for asthma Pub Date : 2021-11-01 DOI:10.1136/thorax-2021-btsabstracts.93

G. Tavernier, M. Philbin, L. Holmes, L. Elsey, D. Allen, S. Fowler

{"title":"持续痰嗜酸性粒细胞增多症无应答者从美波珠单抗切换到贝纳利珠单抗时的严重哮喘结局","authors":"G. Tavernier, M. Philbin, L. Holmes, L. Elsey, D. Allen, S. Fowler","doi":"10.1136/thorax-2021-btsabstracts.93","DOIUrl":null,"url":null,"abstract":"QUEST experienced fewer exacerbations during both studies. Over 80% of patients who achieved 100mL or 200mL pre-bronchodilator FEV1 improvements at the end of QUEST maintained these improvements in TRAVERSE. Conclusions Greater improvements in pre-bronchodilator FEV1 in QUEST led to long-term enhanced benefits of dupilumab treatment; patients maintained these improvements and had fewer exacerbations during TRAVERSE.","PeriodicalId":334138,"journal":{"name":"Biologics for asthma","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"S87 Severe asthma outcomes when switching from mepolizumab to benralizumab in non-responders with persistent sputum eosinophilia\",\"authors\":\"G. Tavernier, M. Philbin, L. Holmes, L. Elsey, D. Allen, S. Fowler\",\"doi\":\"10.1136/thorax-2021-btsabstracts.93\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"QUEST experienced fewer exacerbations during both studies. Over 80% of patients who achieved 100mL or 200mL pre-bronchodilator FEV1 improvements at the end of QUEST maintained these improvements in TRAVERSE. Conclusions Greater improvements in pre-bronchodilator FEV1 in QUEST led to long-term enhanced benefits of dupilumab treatment; patients maintained these improvements and had fewer exacerbations during TRAVERSE.\",\"PeriodicalId\":334138,\"journal\":{\"name\":\"Biologics for asthma\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biologics for asthma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/thorax-2021-btsabstracts.93\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics for asthma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/thorax-2021-btsabstracts.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在两项研究中，QUEST的病情恶化较少。超过80%在QUEST结束时达到100mL或200mL支气管扩张剂前FEV1改善的患者在TRAVERSE中保持了这些改善。结论:支气管扩张剂前FEV1的显著改善导致dupilumab治疗的长期获益增强;患者在TRAVERSE期间保持了这些改善，并且病情恶化较少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

S87 Severe asthma outcomes when switching from mepolizumab to benralizumab in non-responders with persistent sputum eosinophilia

QUEST experienced fewer exacerbations during both studies. Over 80% of patients who achieved 100mL or 200mL pre-bronchodilator FEV1 improvements at the end of QUEST maintained these improvements in TRAVERSE. Conclusions Greater improvements in pre-bronchodilator FEV1 in QUEST led to long-term enhanced benefits of dupilumab treatment; patients maintained these improvements and had fewer exacerbations during TRAVERSE.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biologics for asthma

自引率

0.00%

发文量